Current status of tumor M2 pyruvate kinase (tumor M2-PK) as a biomarker of gastrointestinal malignancy
Current status of tumor M2 pyruvate kinase (tumor M2-PK) as a biomarker of gastrointestinal malignancy
复制标题
DOI：
10.1245/s10434-007-9481-x
复制
发表时间：
2007-10-01
影响因子：
3.7
通讯作者：
Siriwardena, Ajith K.
中科院分区：
文献类型：
--
作者：
Hathurusinghe, Harsha R.;Goonetilleke, Kolitha S.;Siriwardena, Ajith K.
背景：肿瘤丙酮酸激酶M2（tumor M2-PK）是肿瘤组织代谢改变的关键酶。在癌症中，已知它以高浓度存在于恶性组织、血浆和其他体液中。存在用于检测肿瘤M2-PK的商业酶联免疫吸附测定（ELISA）方法。本研究进行了系统的回顾，目前的文献肿瘤M2-PK作为一种诊断工具，并提供了一个概述，目前的使用和范围的这种新兴的biomarkers.Methods：MEDINE和EMBASE数据库进行了搜索，英文文章包含原始数据。使用的MeSH标题为丙酮酸激酶、肿瘤和癌症。所有的病例报告和评论文章被排除，并最终研究人口的30个手稿包含原始data.Results：8篇文章评价血浆肿瘤M2-PK在511食管-胃癌，226胰胆管癌和470结直肠癌患者。虽然有研究间的变化，在截止点，一致的结果包括恶性肿瘤患者的水平升高，升高的程度对应于疾病的程度。结论：肿瘤M2-PK升高的范围内的胃肠道恶性肿瘤。在胰胆管恶性肿瘤，证据的重量表明，该测试可以作为一个连续的诊断测试结合CA 19-9，它也可能是一个有价值的生物标志物的不良预后。粪便肿瘤M2-PK似乎是结肠癌的一种有希望的检测方法。
Background: Tumor pyruvate kinase M2 (tumor M2-PK) is a key enzyme in the altered metabolism of tumor tissue. In cancer, it is known to be present in high concentrations in malignant tissue, plasma and other body fluids. A commercial enzyme-linked immunosorbent assay (ELISA) method exists for the detection of tumor M2-PK. This study undertakes a systematic review of the current literature on tumor M2-PK as a diagnostic tool and provides an overview of the current usage and scope of this emerging biomarker.Methods: The MEDINE and EMBASE databases were searched for English-language articles containing original data. MeSH headings used were pyruvate kinase, tumor and cancer. All case reports and review articles were excluded and a final study population of 30 manuscripts containing original data was obtained.Results: Eight articles evaluated plasma tumor M2-PK in 511 esophago-gastric cancer, 226 pancreatobiliary cancer and 470 colorectal cancer patients. Although there are inter-study variations in cut-off points, consistent findings include elevated levels in patients with malignancy with the degree of elevation corresponding to extent of disease.Conclusion: Tumor M2-PK is elevated in a range of gastrointestinal malignancy. In pancreatobiliary malignancy, the weight of evidence suggests that the test can be used as an adjunctive diagnostic test in conjunction with CA 19-9 and also that it may be a valuable biomarker of adverse prognosis. Stool tumor M2-PK appears to be a promising test for colon cancer.